دورية أكاديمية
The Role of Janus Kinase/STAT3 Pathway in Hematologic Malignancies With an Emphasis on Epigenetics.
| العنوان: | The Role of Janus Kinase/STAT3 Pathway in Hematologic Malignancies With an Emphasis on Epigenetics. |
|---|---|
| المؤلفون: | Zeinalzadeh E; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.; Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Valerievich Yumashev A; Department of Prosthetic Dentistry, Sechenov First Moscow State Medical University, Moscow, Russia., Rahman HS; College of Medicine, University of Sulaimani, Sulaimaniyah, Iraq.; Department of Medical Laboratory Sciences, Komar University of Science and Technology, Sulaimaniyah, Iraq., Marofi F; Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran., Shomali N; Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Kafil HS; German Cancer Research Center, Toxicology and Chemotherapy Unit (G401), Heidelberg, Germany., Solali S; Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Sajjadi-Dokht M; Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Vakili-Samiani S; Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Jarahian M; German Cancer Research Center, Toxicology and Chemotherapy Unit (G401), Heidelberg, Germany., Hagh MF; Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.; Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. |
| المصدر: | Frontiers in genetics [Front Genet] 2021 Dec 21; Vol. 12, pp. 703883. Date of Electronic Publication: 2021 Dec 21 (Print Publication: 2021). |
| نوع المنشور: | Journal Article; Review; Retracted Publication |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101560621 Publication Model: eCollection Cited Medium: Print ISSN: 1664-8021 (Print) Linking ISSN: 16648021 NLM ISO Abbreviation: Front Genet Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Research Foundation. |
| مستخلص: | The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway has been known to be involved in cell growth, cellular differentiation processes development, immune cell survival, and hematopoietic system development. As an important member of the STAT family, STAT3 participates as a major regulator of cellular development and differentiation-associated genes. Prolonged and persistent STAT3 activation has been reported to be associated with tumor cell survival, proliferation, and invasion. Therefore, the JAK-STAT pathway can be a potential target for drug development to treat human cancers, e.g., hematological malignancies. Although STAT3 upregulation has been reported in hematopoietic cancers, protein-level STAT3 mutations have also been reported in invasive leukemias/lymphomas. The principal role of STAT3 in tumor cell growth clarifies the importance of approaches that downregulate this molecule. Epigenetic modifications are a major regulatory mechanism controlling the activity and function of STAT3. So far, several compounds have been developed to target epigenetic regulatory enzymes in blood malignancies. Here, we discuss the current knowledge about STAT3 abnormalities and carcinogenic functions in hematopoietic cancers, novel STAT3 inhibitors, the role of epigenetic mechanisms in STAT3 regulation, and targeted therapies, by focusing on STAT3-related epigenetic modifications. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Zeinalzadeh, Valerievich Yumashev, Rahman, Marofi, Shomali, Kafil, Solali, Sajjadi-Dokht, Vakili-Samiani, Jarahian and Hagh.) |
| التعليقات: | Retraction in: Front Genet. 2023 Sep 04;14:1285098. (PMID: 37732321) |
| References: | J Clin Invest. 2013 Apr;123(4):1580-9. (PMID: 23454751) Cell Stem Cell. 2017 Oct 5;21(4):489-501.e7. (PMID: 28965767) PLoS Genet. 2018 Jun 7;14(6):e1007362. (PMID: 29879107) J Exp Clin Cancer Res. 2019 May 14;38(1):195. (PMID: 31088482) BMC Genomics. 2013 Jan 16;14:4. (PMID: 23324445) Epigenetics. 2019 Dec;14(12):1164-1176. (PMID: 31282279) Leuk Res. 2008 Jul;32(7):1005-14. (PMID: 18192010) Oncol Lett. 2016 Nov;12(5):3045-3050. (PMID: 27899961) Ginekol Pol. 2017;88(10):543-551. (PMID: 29192415) Leukemia. 2017 Aug;31(8):1686-1694. (PMID: 27890932) Blood. 2020 Nov 12;136(20):2334-2345. (PMID: 32844992) Cancers (Basel). 2013 Apr 15;5(2):430-61. (PMID: 24216985) Cancers (Basel). 2020 Mar 09;12(3):. (PMID: 32182763) J Immunother Cancer. 2018 Nov 16;6(1):119. (PMID: 30446007) Blood. 2004 Jun 15;103(12):4630-5. (PMID: 14976049) Toxicol Lett. 2014 Mar 21;225(3):488-97. (PMID: 24440346) Leukemia. 2012 May;26(5):1030-7. (PMID: 22193968) Oncogene. 2000 May 15;19(21):2548-56. (PMID: 10851053) J Gastrointest Cancer. 2020 Mar;51(1):267-270. (PMID: 31073863) J Immunol. 2017 Apr 1;198(7):2712-2720. (PMID: 28193828) Gastroenterology. 2007 Jan;132(1):384-96. (PMID: 17241887) Cell Cycle. 2014;13(21):3331-5. (PMID: 25485578) Blood. 2008 Jun 15;111(12):5663-71. (PMID: 17984313) Cytokine. 2016 Nov;87:26-36. (PMID: 27349799) J Clin Invest. 2010 Oct;120(10):3578-93. (PMID: 20852385) Am J Clin Pathol. 2010 Nov;134(5):826-34. (PMID: 20959668) Front Oncol. 2018 Dec 11;8:566. (PMID: 30619733) Oncogene. 2004 Oct 7;23(46):7726-33. (PMID: 15361843) J Cell Physiol. 2020 May;235(5):4120-4134. (PMID: 31691976) Semin Cell Dev Biol. 2008 Aug;19(4):341-50. (PMID: 18621135) Cell Cycle. 2010 Sep 1;9(17):3423-7. (PMID: 20818158) Leukemia. 2014 Feb;28(2):248-57. (PMID: 23797472) Blood. 2018 Sep 13;132(11):1146-1158. (PMID: 30054295) Int Immunol. 2002 Nov;14(11):1263-71. (PMID: 12407017) J Hematol Oncol. 2013 Dec 05;6:90. (PMID: 24308725) Genes (Basel). 2017 May 25;8(6):. (PMID: 28587062) J Cell Physiol. 2019 Jun;234(6):8203-8220. (PMID: 30500074) Asian Pac J Cancer Prev. 2015;16(6):2219-25. (PMID: 25824741) FEBS J. 2015 May;282(9):1786-800. (PMID: 25369368) Leukemia. 2005 Jun;19(6):936-44. (PMID: 15912144) Cell Rep. 2017 Jan 10;18(2):482-495. (PMID: 28076791) N Engl J Med. 2012 May 17;366(20):1905-13. (PMID: 22591296) Int J Oncol. 2018 Jul;53(1):7-20. (PMID: 29749432) J Biol Chem. 2005 Mar 11;280(10):9627-34. (PMID: 15634679) Antioxid Redox Signal. 2016 Apr 10;24(11):575-89. (PMID: 26649526) Cancer Sci. 2019 Jun;110(6):1931-1946. (PMID: 30974024) Cancers (Basel). 2021 May 26;13(11):. (PMID: 34073410) Front Oncol. 2014 May 01;4:80. (PMID: 24822169) Nat Commun. 2015 Jan 14;6:6025. (PMID: 25586472) Ann Med. 2014 May;46(3):114-22. (PMID: 24512550) Mol Cell. 2014 Jun 5;54(5):716-27. (PMID: 24905005) Cytokine Growth Factor Rev. 2016 Oct;31:1-15. (PMID: 27185365) Blood. 2001 Aug 1;98(3):762-70. (PMID: 11468177) Expert Opin Ther Targets. 2015;19(9):1187-202. (PMID: 26028314) Biochem Biophys Res Commun. 2011 Apr 1;407(1):54-9. (PMID: 21352802) Biochim Biophys Acta. 2013 Jan;1835(1):46-60. (PMID: 23103770) Cell Res. 2018 Oct;28(10):996-1012. (PMID: 30127373) Nat Rev Clin Oncol. 2018 Apr;15(4):234-248. (PMID: 29405201) Clin Epigenetics. 2020 Jan 8;12(1):9. (PMID: 31915063) Oncogene. 2007 Oct 15;26(47):6715-23. (PMID: 17934480) Cell Signal. 2006 Aug;18(8):1117-26. (PMID: 16298512) J Biol Chem. 1999 May 21;274(21):14956-62. (PMID: 10329697) Leuk Lymphoma. 2016 Nov;57(11):2681-4. (PMID: 26952843) Nat Commun. 2018 Feb 8;9(1):583. (PMID: 29422534) PLoS One. 2012;7(10):e48160. (PMID: 23110199) J Immunol. 2007 Mar 1;178(5):2623-9. (PMID: 17312100) Cytokine. 2019 Jun;118:27-34. (PMID: 30031681) Expert Opin Ther Pat. 2013 Jan;23(1):1-17. (PMID: 23094822) Br J Haematol. 2006 Jul;134(2):171-9. (PMID: 16846476) Genes Chromosomes Cancer. 2003 Jul;37(3):300-5. (PMID: 12759928) Haematologica. 2013 Nov;98(11):1748-52. (PMID: 23872306) J Cell Physiol. 2019 Nov;234(11):19366-19383. (PMID: 31020647) Annu Rev Genet. 2007;41:331-68. (PMID: 18076328) IUBMB Life. 2020 Sep;72(9):2034-2044. (PMID: 32687246) Blood. 2010 Apr 8;115(14):2852-63. (PMID: 20154216) Nat Genet. 2003 Mar;33 Suppl:245-54. (PMID: 12610534) Protein Sci. 2018 Dec;27(12):1984-2009. (PMID: 30267440) Pharmacol Res. 2010 Jul;62(1):18-34. (PMID: 20219679) Curr Mol Med. 2021;21(1):15-24. (PMID: 32392112) Brain Behav Immun. 2019 Jul;79:159-173. (PMID: 30763768) Int J Biol Macromol. 2018 Oct 1;117:993-1001. (PMID: 29782972) Oncogene. 2002 Feb 7;21(7):1038-47. (PMID: 11850821) Nat Med. 2007 Nov;13(11):1341-8. (PMID: 17922009) Expert Opin Investig Drugs. 2012 May;21(5):637-55. (PMID: 22493978) Blood. 2009 Apr 23;113(17):4052-62. (PMID: 19144991) Mol Oncol. 2015 Jun;9(6):1194-206. (PMID: 25777967) Oncogene. 2016 Dec 15;35(50):6439-6445. (PMID: 27212035) Anticancer Drugs. 2005 Jul;16(6):601-7. (PMID: 15930886) Oncogene. 2000 May 15;19(21):2511-22. (PMID: 10851050) Front Oncol. 2019 Feb 21;9:48. (PMID: 30847297) BMC Res Notes. 2020 Dec 29;13(1):568. (PMID: 33375941) Cancer Chemother Pharmacol. 2010 May;65(6):1039-46. (PMID: 19701750) Clin Cancer Res. 2015 Feb 15;21(4):833-43. (PMID: 25501124) Oncogene. 2016 Feb 25;35(8):939-51. (PMID: 25982279) Signal Transduct Target Ther. 2019 Dec 17;4:62. (PMID: 31871779) NPJ Breast Cancer. 2018 May 4;4:10. (PMID: 29761158) J Med Chem. 2010 Dec 23;53(24):8468-84. (PMID: 21105711) Med Oncol. 2015 Feb;32(2):453. (PMID: 25603952) Expert Opin Biol Ther. 2013 Sep;13(9):1273-85. (PMID: 23859704) Cancer Lett. 2018 Sep 1;431:123-141. (PMID: 29857127) Stem Cells. 2012 Dec;30(12):2645-56. (PMID: 22968989) Expert Opin Investig Drugs. 2017 Aug;26(8):883-887. (PMID: 28714740) Cell. 1992 Jul 24;70(2):313-22. (PMID: 1386289) Cancers (Basel). 2020 Jan 18;12(1):. (PMID: 31963765) J Interferon Cytokine Res. 2016 Apr;36(4):226-37. (PMID: 26716518) Cell Biol Int. 2020 Feb;44(2):368-380. (PMID: 31579983) Nat Clin Pract Oncol. 2005 Jun;2(6):315-24. (PMID: 16264989) |
| فهرسة مساهمة: | Keywords: Janus kinase; STAT3; epigenetics; leukemia; methylation |
| تواريخ الأحداث: | Date Created: 20220107 Latest Revision: 20230921 |
| رمز التحديث: | 20230921 |
| مُعرف محوري في PubMed: | PMC8725977 |
| DOI: | 10.3389/fgene.2021.703883 |
| PMID: | 34992627 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-8021 |
|---|---|
| DOI: | 10.3389/fgene.2021.703883 |